Literature DB >> 23113613

Clinical characteristics of eosinophilic and noneosinophilic asthma in children.

Yong Ju Lee1, Kyung Won Kim, Bong Seok Choi, Myung Hyun Sohn, Kyu-Earn Kim.   

Abstract

AIM: Asthma is a heterogeneous and complex chronic inflammatory disease of the airways. Asthma can be classified as eosinophilic asthma (EA) or noneosinophilic asthma (NEA). We investigated whether children with EA manifest different clinical characteristics than those with NEA.
METHODS: We enrolled 288 steroid-naive asthmatic children and classified them, based on the cell counts in induced sputum, into EA (158 children) and NEA (89 children) groups.
RESULTS: No significant differences were observed between the groups with regard to age, sex, family history of atopy, secondary smoking or asthma exacerbations. Moderate-to-severe asthma was more frequent in the EA group than in the NEA group. Blood eosinophil counts and serum eosinophil cationic protein were higher in EA patients than in NEA patients. The forced expiratory volume in 1 sec was lower in children with EA than in those with NEA (% of predicted value, 88.6 ± 18.5 vs. 93.6 ± 15.6, p < 0.05). The sputum eosinophil (in EA) and neutrophil (in NEA) counts increased with increasing asthma severity.
CONCLUSION: Airway inflammation, especially eosinophilic inflammation, was associated with asthma severity and reduced pulmonary function in children. ©2012 The Author(s)/Acta Paediatrica ©2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2012        PMID: 23113613     DOI: 10.1111/apa.12046

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  4 in total

1.  Associations of wheezing phenotypes with late asthma outcomes in the Avon Longitudinal Study of Parents and Children: A population-based birth cohort.

Authors:  Raquel Granell; A John Henderson; Jonathan A Sterne
Journal:  J Allergy Clin Immunol       Date:  2016-04-20       Impact factor: 10.793

2.  Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children.

Authors:  Sheel N Shah; Jocelyn R Grunwell; Ahmad F Mohammad; Susan T Stephenson; Gerald B Lee; Brian P Vickery; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-27

Review 3.  Anti-inflammatory dimethylfumarate: a potential new therapy for asthma?

Authors:  Petra Seidel; Michael Roth
Journal:  Mediators Inflamm       Date:  2013-03-27       Impact factor: 4.711

4.  Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma.

Authors:  Steven W Yancey; Hector G Ortega; Oliver N Keene; Eric S Bradford
Journal:  Allergy Asthma Clin Immunol       Date:  2019-09-03       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.